"MELK inhibitor, novel molecular targeted therapeutics for human cancer stem cells." Cell Cycle, 12(11), pp. 1655–1656
Cell Cycle
Volume 12, 2013 - Issue 11
![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Related Research Data
Recruitment of the Actin-binding Protein HIP-55 to the Immunological Synapse Regulates T Cell Receptor Signaling and Endocytosis
Source:
Elsevier BV
OTSSP167 Abrogates Mitotic Checkpoint through Inhibiting Multiple Mitotic Kinases.
Source:
Public Library of Science (PLoS)
MELK—a conserved kinase: functions, signaling, cancer, and controversy
Source:
Springer Science and Business Media LLC
Maternal Embryonic Leucine Zipper Kinase/Murine Protein Serine-Threonine Kinase 38 Is a Promising Therapeutic Target for Multiple Cancers
Source:
American Association for Cancer Research (AACR)
Exploiting replicative stress to treat cancer
Source:
Springer Science and Business Media LLC
Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family.
Source:
Springer Science and Business Media LLC
Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer.
Source:
Impact Journals, LLC
Linking provided by
